PURPOSE: To compare processes of care and survival for breast cancer by hospital volume in Belgium, based on 11 validated process quality indicators. METHODS: Three databases were linked at the patient level: the Cancer Registry, the population and the claims databases. All women with a diagnosis of invasive breast cancer between 2004 and 2006 were selected. Hospitals were classified according to their annual volume of treated patients: <50 (very low), 50-99 (low), 100-149 (medium) and ≥ 150 patients (high). Cox and logistic regression models were used to test differences in 5-year survival and in achievement of process indicators across volume categories, adjusting for age, tumor grade and stage. RESULTS: A total of 25178 women with invasive breast cancer were treated in 111 hospitals. Half of the hospitals (N=57) treated <50 patients per year. Six of eleven process indicators showed higher rates in high-volume hospitals: multidisciplinary team meeting, cytological and/or histological assessment before surgery, use of neoadjuvant chemotherapy, breast-conserving surgery rate, adjuvant radiotherapy after breast-conserving surgery, and follow-up mammography. Higher volume was also associated with improved survival. The 5-year observed survival rates were 74.9%, 78.8%, 79.8% and 83.9% for patients treated in very-low-, low-, medium- and high-volume hospitals respectively. After case-mix adjustment, patients treated in very-low- or low-volume hospitals had a hazard ratio for death of 1.26 (95% CI 1.12, 1.42) and 1.15 (95% CI 1.01, 1.30) respectively compared with high-volume hospitals. CONCLUSION: Survival benefits reported in high-volume hospitals suggest a better application of recommended processes of care, justifying the centralization of breast cancer care in such hospitals.
PURPOSE: To compare processes of care and survival for breast cancer by hospital volume in Belgium, based on 11 validated process quality indicators. METHODS: Three databases were linked at the patient level: the Cancer Registry, the population and the claims databases. All women with a diagnosis of invasive breast cancer between 2004 and 2006 were selected. Hospitals were classified according to their annual volume of treated patients: <50 (very low), 50-99 (low), 100-149 (medium) and ≥ 150 patients (high). Cox and logistic regression models were used to test differences in 5-year survival and in achievement of process indicators across volume categories, adjusting for age, tumor grade and stage. RESULTS: A total of 25178 women with invasive breast cancer were treated in 111 hospitals. Half of the hospitals (N=57) treated <50 patients per year. Six of eleven process indicators showed higher rates in high-volume hospitals: multidisciplinary team meeting, cytological and/or histological assessment before surgery, use of neoadjuvant chemotherapy, breast-conserving surgery rate, adjuvant radiotherapy after breast-conserving surgery, and follow-up mammography. Higher volume was also associated with improved survival. The 5-year observed survival rates were 74.9%, 78.8%, 79.8% and 83.9% for patients treated in very-low-, low-, medium- and high-volume hospitals respectively. After case-mix adjustment, patients treated in very-low- or low-volume hospitals had a hazard ratio for death of 1.26 (95% CI 1.12, 1.42) and 1.15 (95% CI 1.01, 1.30) respectively compared with high-volume hospitals. CONCLUSION: Survival benefits reported in high-volume hospitals suggest a better application of recommended processes of care, justifying the centralization of breast cancer care in such hospitals.
Authors: Antonio Ponti; Elsebeth Lynge; Ted James; Ondřej Májek; My von Euler-Chelpin; Ahti Anttila; Patricia Fitzpatrick; Maria Piera Mano; Masaaki Kawai; Astrid Scharpantgen; Jacques Fracheboud; Solveig Hofvind; Carmen Vidal; Nieves Ascunce; Dolores Salas; Jean-Luc Bulliard; Nereo Segnan; Karla Kerlikowske; Stephen Taplin Journal: Eur J Cancer Date: 2014-08-19 Impact factor: 9.162
Authors: Rachel A Greenup; Samilia Obeng-Gyasi; Samantha Thomas; K Houck; Whitney O Lane; Rachel C Blitzblau; Terry Hyslop; E Shelley Hwang Journal: Ann Surg Date: 2018-02 Impact factor: 12.969
Authors: Brian T Kadow; Shreyas S Joshi; Alexander Kutikov; Elizabeth Handorf; Marc C Smaldone; Robert G Uzzo; Daniel M Geynisman Journal: Ann Transl Med Date: 2019-12
Authors: Tina W F Yen; Zhuping Garacci; Purushottam W Laud; Liliana E Pezzin; Ann B Nattinger Journal: Breast Cancer Date: 2021-01-04 Impact factor: 4.239
Authors: Nicolas J Chin-Yee; Andrew T Yan; Alexander Kumachev; Dennis Ko; Craig Earle; George Tomlinson; Maureen E Trudeau; Murray Krahn; Monika Krzyzanowska; Raveen Pal; Christine Brezden-Masley; Scott Gavura; Kelly Lien; Kelvin Chan Journal: CMAJ Open Date: 2016-02-18